HUTCHMED Strengthens Board with New Appointment
HUTCHMED (China) Limited is pleased to announce the appointment of Mr. Wong Tak Wai as an Independent Non-executive Director, effective from the first week of March 2025. This significant addition to the board signals HUTCHMED's commitment to enhancing its governance and strategic oversight as it navigates the evolving landscape of biopharmaceuticals.
Mr. Wong's Extensive Background in Finance
Bringing over 35 years of vast experience in accounting and corporate finance, Mr. Wong has played an instrumental role in guiding companies through stock exchange listings and executing numerous mergers and acquisitions throughout his career. His journey reached a notable milestone when he retired as a partner from PricewaterhouseCoopers in 2017, leaving behind a legacy of professionalism and expertise.
A Warm Welcome from the Chairman
Dr. Dan Eldar, Chairman of HUTCHMED, expressed enthusiasm about Mr. Wong's appointment, stating, “We are delighted to welcome Mr. Wong to our board. His extensive experience in finance and accounting will be key as we work towards the strategic growth of HUTCHMED.” This confidence underscores the crucial role that seasoned professionals play in steering the company towards success.
Mr. Wong's Current Roles and Responsibilities
At 68 years old, Mr. Wong is not new to leadership roles within the industry. He currently serves as a non-executive director at Melbourne Enterprises Limited, enhancing his portfolio of governance responsibilities. His previous accolades include positions at the Hong Kong Institute of Certified Public Accountants (HKICPA), where he notably chaired the auditing standards committee.
Commitment to Sustainable Development
Moreover, Mr. Wong’s involvement with the Sustainable Agricultural Development Fund Advisory Committee reflects his dedication to integrating sustainability within business practices, an increasingly crucial element in today’s corporate responsibilities.
Director’s Fee Structure and Term
Under the terms of his appointment, Mr. Wong will receive a director’s fee of US$76,000 per annum. This fee, alongside US$13,500 for his role on the Audit Committee, is reflective of his responsibilities and market standards. His appointment will initially last until the next annual general meeting, ensuring that he will continue to contribute strategically as HUTCHMED progresses.
About HUTCHMED
As an innovative biopharmaceutical company, HUTCHMED focuses on the discovery and commercialization of targeted therapies aimed at treating cancer and immunological diseases. With its commitment to developing superior treatment options, HUTCHMED has successfully brought multiple medicines to market, with the first receiving international recognition by being approved in the US, Europe, and Japan.
For more details, visit www.hutch-med.com or connect with HUTCHMED on social media platforms.
Frequently Asked Questions
What is the role of Mr. Wong at HUTCHMED?
Mr. Wong is appointed as an Independent Non-executive Director and serves on the Audit Committee, contributing his extensive experience in finance and accounting.
How does the board believe Mr. Wong will contribute?
The board believes Mr. Wong's vast knowledge in finance will significantly enhance strategic decision-making and governance in the company.
What is Mr. Wong’s background?
Mr. Wong has over 35 years of experience in accounting, auditing, and corporate finance and was previously a partner at PricewaterhouseCoopers.
What are Mr. Wong’s professional affiliations?
Mr. Wong is a Fellow of the HKICPA and an Associate of the Institute of Chartered Accountants of Australia and New Zealand.
What does HUTCHMED specialize in?
HUTCHMED specializes in developing targeted therapies and immunotherapies focused on cancer and immunological diseases, with successful product launches in multiple markets.
